Pfizer says virus vaccine 90% effective

·1-min read

The coronavirus vaccine candidate developed by US pharma giant Pfizer together with Germany's BioNTech is 90 per cent effective in preventing COVID-19, the firms say.

An analysis of the phase 3 trial showed the vaccine was largely effective in preventing COVID-19 in participants "without prior evidence of SARS-Cov-2 infection," according to the companies' joint statement.

More than 43,500 people have been enrolled in the phase 3 trial since late July.

The two companies said they would likely apply for emergency use authorisation of the vaccine with the US Food and Drug Administration in the coming week.